Randomized double blind placebo-controlled clinical safety, tolerability and pharmacokinetic/-dynamic study on the effects of escalating single intravenous doses of EA-230 on the innate immune response during experimental human endotoxemia - PK/PD of EA-230 during endotoxemia

Exponential Biotherapies inc.0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年4月23日

试验速览

暂无简介。

•1.Written informed consent to participate in this trial prior to any study-mandated procedure.
•2.Subjects aged 18 to 35 years inclusive, for part 2 only male subjects will be included.
•3.Subjects and their partners have to agree to use a reliable way of contraception from study entry until 3 months after study drug administration.
•4.BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg
•5.Healthy as determined by medical history, physical examination, vital signs, 12 lead electrocardiogram, and clinical laboratory parameters
•6.Negative results for hard drug use from urine drug screen at screening

•1.Unwillingness to abstain from any medication, recreational drugs or anti-oxidant vitamin supplements during the course of the study and within 7 days prior to study Day 1.
•2.Unwillingness to abstain from nicotine, or alcohol or within 1 day prior to study Day 1
•3.Previous participation in a trial where LPS was administered
•4.Surgery or trauma with significant blood loss or blood donation within 3 months prior to studyDay 1
•5.History, signs or symptoms of cardiovascular disease, in particular:
•History of frequent vaso-vagal collapse or of orthostatic hypotension
•Resting pulse rate <=45 or >=100 beats / min
•Hypertension (RR systolic >160 or RR diastolic >90)
•Hypotension (RR systolic <100 or RR diastolic <50)
•conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complex bundle branch block
•6.Renal impairment: plasma creatinine >120 µmol/L
•7.Liver function tests (alkaline phosphatase, AST, ALT and/or γ-GT) above 2x the upper limit of normal

发起方